Share
array:23 [ "pii" => "S0300289623003587" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.10.006" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3421" "copyright" => "SEPAR" "copyrightAnyo" => "2023" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Arch Bronconeumol. 2024;60:55-8" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S0300289623003630" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.10.010" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3426" "copyright" => "The Authors" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Arch Bronconeumol. 2024;60:59-61" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>" "titulo" => "Alveolar Macrophage Expression Differs According to Lung Cancer Subtype" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "59" "paginaFinal" => "61" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1031 "Ancho" => 2508 "Tamanyo" => 244407 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Characterization of alveolar macrophage populations. (A) M2/M1 ratio according to definitive diagnosis. (B) Different examples of flow cytometry of included patients. SCLC: small cell lung cancer, SSC: side scatter channel, FSC: forward scatter channel.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Violeta Esteban, Javier Javaloyes, Sebastián Martínez-López, Jose Norberto Sancho-Chust, Beatriz Gálvez, Eusebi Chiner, Consuelo Ferrer, María Francisca Colom" "autores" => array:8 [ 0 => array:2 [ "nombre" => "Violeta" "apellidos" => "Esteban" ] 1 => array:2 [ "nombre" => "Javier" "apellidos" => "Javaloyes" ] 2 => array:2 [ "nombre" => "Sebastián" "apellidos" => "Martínez-López" ] 3 => array:2 [ "nombre" => "Jose Norberto" "apellidos" => "Sancho-Chust" ] 4 => array:2 [ "nombre" => "Beatriz" "apellidos" => "Gálvez" ] 5 => array:2 [ "nombre" => "Eusebi" "apellidos" => "Chiner" ] 6 => array:2 [ "nombre" => "Consuelo" "apellidos" => "Ferrer" ] 7 => array:2 [ "nombre" => "María Francisca" "apellidos" => "Colom" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003630?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003630/v3_202406051404/en/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0300289623003629" "issn" => "03002896" "doi" => "10.1016/j.arbres.2023.11.001" "estado" => "S300" "fechaPublicacion" => "2024-01-01" "aid" => "3425" "copyright" => "SEPAR" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Arch Bronconeumol. 2024;60:54" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Clinical Image</span>" "titulo" => "Cryptococcal Lymphadenitis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "54" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Fig. 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 768 "Ancho" => 1533 "Tamanyo" => 200745 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Volume-rendered CT (A) and axial unenhanced images (B) showed multiple swollen and partially fused lymph nodes in the hilar (white arrows) and mediastinal (red arrowheads) areas, with the largest one measuring 5<span class="elsevierStyleHsp" style=""></span>cm<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>3<span class="elsevierStyleHsp" style=""></span>cm, causing the compression of right and left main bronchus (blue arrows). Axial CT contrast-enhanced image (C) demonstrated slight enhancement of the swollen lymph nodes. At six-month follow-up, chest CT (D and E) showed the shrinkage of lymph nodes and the relief of main bronchus compression. H&E staining (F) demonstrated numerous spherical yeast cells of variable size surrounded by a clear halo (400×), suggesting the diagnosis of cryptococcosis.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jia He, Xian-Zheng Tan, Peng Liu" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Jia" "apellidos" => "He" ] 1 => array:2 [ "nombre" => "Xian-Zheng" "apellidos" => "Tan" ] 2 => array:2 [ "nombre" => "Peng" "apellidos" => "Liu" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003629?idApp=UINPBA00003Z" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003629/v3_202406051404/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Scientific Letter</span>" "titulo" => "Efficacy and Safety of Single-inhaler Triple Therapy Containing Dual Bronchodilator With Corticosteroids Compared to Monotherapy, Dual Therapy, or Open Triple Therapy in Moderate/Severe COPD: A Systematic Literature Review" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">To the Director</span>," "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "55" "paginaFinal" => "58" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Juan Antonio Riesco Miranda, Myriam Calle Rubio, David Díaz Pérez, Jose Luis López-Campos, Juan Antonio Trigueros Carrero, Bartolomé Celli" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Juan Antonio" "apellidos" => "Riesco Miranda" "email" => array:1 [ 0 => "jantonio.riesco@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Myriam" "apellidos" => "Calle Rubio" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "David" "apellidos" => "Díaz Pérez" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "Jose Luis" "apellidos" => "López-Campos" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] ] ] 4 => array:3 [ "nombre" => "Juan Antonio" "apellidos" => "Trigueros Carrero" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 5 => array:3 [ "nombre" => "Bartolomé" "apellidos" => "Celli" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] ] ] ] "afiliaciones" => array:6 [ 0 => array:3 [ "entidad" => "Servicio de Neumología, Hospital San Pedro de Alcántara, Ciberes, Cáceres, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Neumología, Hospital Universitario Clínico San Carlos, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Neumología y Cirugía Torácica, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Unidad Médico-Quirúrgica de Enfermedades Respiratorias, Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/Universidad de Sevilla, Sevilla, Spain" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Centro de salud Menasalbas, Menasalbas, Toledo, Spain" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Pulmonary and Critical Care Division, Brigham and Women's Hospital, Harvard University Medical School, Boston, MA, USA" "etiqueta" => "f" "identificador" => "aff0030" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">We performed a systematic literature review and meta-analysis to assess the efficacy and safety of single-inhaler triple therapy (SITT) compared to monotherapy, dual therapy, and open TT (OTT), at 52 weeks, in five predefined subgroups of moderate/severe COPD patients (see <a class="elsevierStyleCrossRef" href="#sec0055">supplementary material</a>).</p><p id="par0010" class="elsevierStylePara elsevierViewall">We included nine articles from five randomized controlled trials of good quality.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">1–9</span></a> The studies analyzed mortality,<a class="elsevierStyleCrossRefs" href="#bib0110"><span class="elsevierStyleSup">3,4</span></a> rate of moderate and severe exacerbations,<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">2,5–10</span></a> changes in the FEV<span class="elsevierStyleInf">1</span>,<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">1,6,8,9</span></a> dyspnea (using the Transition Dyspnea Index [TDI]),<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a> and quality of life (using the St. George's Respiratory Questionnaire [SGRQ]).<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">1,6,9</span></a></p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Previous Exacerbation History</span><p id="par0015" class="elsevierStylePara elsevierViewall">In the FULFIL trial, SITT was associated with a lower rate of moderate-to-severe exacerbations than LABA/ICS in patients with ≥<span class="elsevierStyleHsp" style=""></span>1 severe exacerbation (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05), but there were no differences in patients with ≥<span class="elsevierStyleHsp" style=""></span>2 moderate exacerbations. Besides, SITT significantly improved trough FEV<span class="elsevierStyleInf">1</span> compared to LABA/ICS in patients with ≥<span class="elsevierStyleHsp" style=""></span>2 moderate exacerbations (difference: 199<span class="elsevierStyleHsp" style=""></span>ml) or ≥<span class="elsevierStyleHsp" style=""></span>1 severe exacerbation (difference: 166<span class="elsevierStyleHsp" style=""></span>ml), but also in those with FEV<span class="elsevierStyleInf">1</span> ≥<span class="elsevierStyleHsp" style=""></span>50–<<span class="elsevierStyleHsp" style=""></span>80% and ≥<span class="elsevierStyleHsp" style=""></span>2 moderate exacerbations or ≥<span class="elsevierStyleHsp" style=""></span>1 severe exacerbation (difference: 179<span class="elsevierStyleHsp" style=""></span>ml).<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a> However, improvements in SGRQ with SITT compared to LAMA/ICS were only statistically significant (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.026) in patients with ≥<span class="elsevierStyleHsp" style=""></span>2 moderate exacerbations.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">The IMPACT trial found that SITT in patients with ≥<span class="elsevierStyleHsp" style=""></span>2 moderate/severe exacerbations resulted in a reduction in the annual rate of exacerbations compared to LABA/ICS (difference: 11%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.01) and LAMA/LABA (difference: 28%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001).<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a> But in the TRIBUTE study, there was no difference in the exacerbation rate between SITT and LAMA/LABA in patients with ><span class="elsevierStyleHsp" style=""></span>1 exacerbation.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The ETHOS trial compared SITT at two ICS dose levels with LABA/ICS and LAMA/LABA.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a> Except for SITT at the low ICS dose level, the rate of moderate or severe exacerbations was significantly lower with SITT than with LABA/ICS and LAMA/LABA in patients with ≥<span class="elsevierStyleHsp" style=""></span>2 exacerbations.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a> Another analysis reported a significantly lower risk of death with SITT compared to LAMA/LABA in patients with ≥<span class="elsevierStyleHsp" style=""></span>2 moderate or severe exacerbations: HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.36 (95% CI 0.19–0.70) and HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.55 (95% CI 0.32–0.97) for SITT at high (320<span class="elsevierStyleHsp" style=""></span>μg) and low (160<span class="elsevierStyleHsp" style=""></span>μg) ICS dose levels.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> No differences were observed compared to LABA/ICS in patients with ≥<span class="elsevierStyleHsp" style=""></span>1 severe exacerbation.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">The TRINITY study, which included patients with severe and very severe COPD,<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> reported that SITT compared with LAMA and OTT significantly decreased the rate of moderate or severe exacerbations in patients with ><span class="elsevierStyleHsp" style=""></span>1 exacerbation (RR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.72, and RR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.71).<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Lung Function and COPD Severity</span><p id="par0035" class="elsevierStylePara elsevierViewall">The FULFIL study showed that SITT significantly improved FEV<span class="elsevierStyleInf">1</span> at 52 weeks compared to LABA/ICS in patients with FEV<span class="elsevierStyleInf">1</span> ≤<span class="elsevierStyleHsp" style=""></span>50% and ≥<span class="elsevierStyleHsp" style=""></span>1 moderate or severe exacerbation (difference: 140<span class="elsevierStyleHsp" style=""></span>ml). The difference was larger (224<span class="elsevierStyleHsp" style=""></span>ml) in patients without a history of exacerbations.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a> No statistical differences in the SGRQ were observed between groups.</p><p id="par0040" class="elsevierStylePara elsevierViewall">A sub analysis of the ETHOS trial revealed that mortality was significantly lower in patients with FEV<span class="elsevierStyleInf">1</span> <<span class="elsevierStyleHsp" style=""></span>50% on SITT at the high ICS dose level (320<span class="elsevierStyleHsp" style=""></span>μg) compared to LAMA/LABA. However, no differences were observed between SITT at both dose levels and LABA/ICS and between SITT at the 160<span class="elsevierStyleHsp" style=""></span>μg dose level and LAMA/LABA.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a></p><p id="par0045" class="elsevierStylePara elsevierViewall">In the TRINITY study,<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> SITT significantly reduced the rate of moderate or severe exacerbations (HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.77, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.050) compared to LAMA, yet not in patients with very severe COPD. Similar findings were reported for changes in FEV<span class="elsevierStyleInf">1</span>. However, there were no differences between SITT and OTT regarding the rate of exacerbations and changes in FEV<span class="elsevierStyleInf">1</span> in patients with severe or very severe COPD.</p></span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Blood Eosinophil Concentration</span><p id="par0050" class="elsevierStylePara elsevierViewall">The IMPACT trial showed that in patients with eosinophil levels ≥<span class="elsevierStyleHsp" style=""></span>150<span class="elsevierStyleHsp" style=""></span>cells/μL, the rate of moderate–severe exacerbations was significantly lower with SITT compared to LABA/ICS and LAMA/LABA, amounting to 0.95%, 1.08%, and 1.39%, respectively.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a> Yet, SITT was only statistically superior to LABA/ICS and not to LAMA/LABA in patients with <<span class="elsevierStyleHsp" style=""></span>150<span class="elsevierStyleHsp" style=""></span>cells/μL.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a></p><p id="par0055" class="elsevierStylePara elsevierViewall">In the ETHOS trial,<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">7</span></a> the rate of moderate or severe exacerbations was significantly lower with SITT (high and low ICS dose levels) than with LABA/ICS and LAMA/LABA in patients with eosinophil counts ≥<span class="elsevierStyleHsp" style=""></span>150<span class="elsevierStyleHsp" style=""></span>cells/μL. In patients with <<span class="elsevierStyleHsp" style=""></span>150<span class="elsevierStyleHsp" style=""></span>cells/μL, both SITT dose levels were significantly superior to LABA/ICS, but no differences were observed with LAMA/LABA.</p><p id="par0060" class="elsevierStylePara elsevierViewall">The IMPACT trial explored the rate of exacerbations and the changes in SGRQ, FEV<span class="elsevierStyleInf">1</span>, and TDI on SITT compared to LAMA/LABA according to different eosinophil level cut-offs (90, ≥<span class="elsevierStyleHsp" style=""></span>90–<<span class="elsevierStyleHsp" style=""></span>140, ≥<span class="elsevierStyleHsp" style=""></span>140–<<span class="elsevierStyleHsp" style=""></span>200, ≥<span class="elsevierStyleHsp" style=""></span>200–<<span class="elsevierStyleHsp" style=""></span>310, and ≥<span class="elsevierStyleHsp" style=""></span>310<span class="elsevierStyleHsp" style=""></span>cells/μL). In general, the magnitude of the benefit on SITT increased proportionally to blood eosinophil count, though the relationship with FEV<span class="elsevierStyleInf">1</span> was less marked.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a></p><p id="par0065" class="elsevierStylePara elsevierViewall">In the TRIBUTE study,<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a> the annual rate of moderate/severe exacerbations was significantly lower on SITT than on LAMA/LABA in patients with eosinophil levels ≥<span class="elsevierStyleHsp" style=""></span>2%, while there were no differences between treatments for levels <<span class="elsevierStyleHsp" style=""></span>2%.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a></p><p id="par0070" class="elsevierStylePara elsevierViewall">In the TRINITY trial,<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> in which patients with eosinophil levels ≥<span class="elsevierStyleHsp" style=""></span>2% had a lower risk of moderate or severe exacerbations with SITT than with LAMA (RR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.70, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.050), there were no differences in patients with eosinophil levels <<span class="elsevierStyleHsp" style=""></span>2%. On the other hand, changes in FEV<span class="elsevierStyleInf">1</span> were significantly greater with SITT than with LAMA in both eosinophil level subgroups (0.07<span class="elsevierStyleHsp" style=""></span>L, and 0.04<span class="elsevierStyleHsp" style=""></span>L, respectively). However, when comparing SITT with OTT, there were no differences in the rate of exacerbations and FEV<span class="elsevierStyleInf">1</span> changes in any eosinophil level subgroups.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Smoking Status</span><p id="par0075" class="elsevierStylePara elsevierViewall">In the IMPACT trial, the reduction in the annual exacerbation rates was significantly more pronounced with SITT than with LABA/ICS and LAMA/LABA, regardless of smoking status.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a> In current smokers, the reduction rates compared to dual therapies were 15% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.01) and 14% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.05), respectively. In former smokers 15% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001) and 30% (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.001).<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">2</span></a> Smoking status had also an impact on several variables, including moderate or severe exacerbations, TDI, and FEV<span class="elsevierStyleInf">1</span>, depending on blood eosinophil count.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">6</span></a></p><p id="par0080" class="elsevierStylePara elsevierViewall">In the TRIBUTE trial, the reduction in the rate of moderate or severe exacerbations was significantly greater with SITT than with LAMA/LABA in current smokers (RR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.77), without differences in former smokers.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">5</span></a></p><p id="par0085" class="elsevierStylePara elsevierViewall">In the TRINITY study, the risk of moderate or severe exacerbations was lower with SITT than with LAMA in current smokers (RR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.76, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.050), with no differences in former smokers.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a> On the other hand, changes in FEV<span class="elsevierStyleInf">1</span> were significantly more marked with SITT than with LAMA in current smokers (difference 0.06<span class="elsevierStyleHsp" style=""></span>L, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.050) and in former smokers (difference 0.06<span class="elsevierStyleHsp" style=""></span>L, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>0.050).</p><p id="par0090" class="elsevierStylePara elsevierViewall">There were no differences between SITT and OTT in the rate of exacerbations and FEV<span class="elsevierStyleInf">1</span> changes in current and former smokers.<a class="elsevierStyleCrossRef" href="#bib0135"><span class="elsevierStyleSup">8</span></a></p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Previous Medications (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>)</span><p id="par0160" class="elsevierStylePara elsevierViewall"></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0095" class="elsevierStylePara elsevierViewall">In the FULFIL trial, SITT was statistically superior to LABA/ICS in reducing exacerbations in patients previously on LABA/ICS and OTT.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a> Improvements in FEV<span class="elsevierStyleInf">1</span> were greater with SITT irrespective of previous medications, but there were no differences when changes in quality of life were analyzed.<a class="elsevierStyleCrossRef" href="#bib0100"><span class="elsevierStyleSup">1</span></a></p><p id="par0100" class="elsevierStylePara elsevierViewall"><span class="elsevierStyleItalic">Post hoc</span> data from the IMPACT study showed that in patients on ICS at screening, mortality was significantly lower with SITT compared to LAMA/LABA (HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.63, 95% CI 0.44–0.89), but no differences were found compared to ICS/LABA.<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a> Besides, the risk of death with SITT compared to LAMA/LABA in patients on OTT at screening was HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.40 (95% CI 0.19–0.84).<a class="elsevierStyleCrossRef" href="#bib0110"><span class="elsevierStyleSup">3</span></a> The reduction in moderate or severe exacerbations was also greater in the SITT group than in the LAMA/LABA group in patients on ICS, LABA/ICS, or OTT at screening, yet with no statistically significant differences in patients with previous LAMA or LAMA/LABA.<a class="elsevierStyleCrossRef" href="#bib0140"><span class="elsevierStyleSup">9</span></a></p><p id="par0105" class="elsevierStylePara elsevierViewall">In the ETHOS trial, there were no differences in mortality between SITT and LABA/ICS in patients with prior ICS or OTT.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a> However, this risk was significantly lower on SITT at the high ICS dose level (budesonide 320<span class="elsevierStyleHsp" style=""></span>μg) than on LAMA/LABA in patients with previous ICS or OTT.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">4</span></a></p><p id="par0110" class="elsevierStylePara elsevierViewall">We did not identify any safety data specifically in the subgroups analyzed.</p><p id="par0115" class="elsevierStylePara elsevierViewall">In the meta-analysis (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>) we found that in patients with ≥<span class="elsevierStyleHsp" style=""></span>2 moderate and/or ≥<span class="elsevierStyleHsp" style=""></span>1 severe exacerbations, SITT resulted in greater reductions in the annual rate of exacerbations compared to LAMA/LABA (HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.73, 95% CI 0.67–0.79), without relevant heterogeneity.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">4,5</span></a> Similar results were observed in patients with high eosinophil levels (HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.70, 95% CI 0.65–0.76), yet with a high and significant heterogeneity (<span class="elsevierStyleItalic">I</span><span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>74.3%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.020). There was also a relevant heterogeneity (<span class="elsevierStyleItalic">I</span><span class="elsevierStyleSup">2</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>83.2%, <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.003) in the rate of exacerbations in patients with high eosinophil levels when comparing SITT and LABA/ICS (HR<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.82, 95% CI 0.76–0.87).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0120" class="elsevierStylePara elsevierViewall">In conclusion, SITT results in more pronounced clinical benefits on exacerbations and lung function compared to other inhaled COPD medications in patients with moderate-to-severe COPD, especially in those at high risk of exacerbations and with high blood eosinophil concentrations. Further evidence (in the long-term, daily practice, etc.) is needed to fully capture the characteristics of patient subgroups that may benefit most from SITT and to identify those with a substantial extra safety risk.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0030">Ethical Approval</span><p id="par0125" class="elsevierStylePara elsevierViewall">This study was performed in line with the principles of the Declaration of Helsinki.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Authors’ Contributions</span><p id="par0130" class="elsevierStylePara elsevierViewall">The study was conceived by all authors, all were involved in the study planning and design. JAR was involved in study delivery, prepared the data and carried out statistical analysis. All authors provided expert opinion on development of the analysis and interpreting the data. JAR and BC developed and wrote the manuscript, with critical revisions and review of the final manuscript from all other authors.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Funding</span><p id="par0135" class="elsevierStylePara elsevierViewall">The study was funded by an unrestricted educational grant from <span class="elsevierStyleGrantSponsor" id="gs1">Chiesi</span>.</p></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Conflict of Interest</span><p id="par0140" class="elsevierStylePara elsevierViewall">The authors declare no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:10 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Previous Exacerbation History" ] 1 => array:2 [ "identificador" => "sec0010" "titulo" => "Lung Function and COPD Severity" ] 2 => array:2 [ "identificador" => "sec0015" "titulo" => "Blood Eosinophil Concentration" ] 3 => array:2 [ "identificador" => "sec0020" "titulo" => "Smoking Status" ] 4 => array:2 [ "identificador" => "sec0025" "titulo" => "Previous Medications (Table 1)" ] 5 => array:2 [ "identificador" => "sec0030" "titulo" => "Ethical Approval" ] 6 => array:2 [ "identificador" => "sec0035" "titulo" => "Authors’ Contributions" ] 7 => array:2 [ "identificador" => "sec0040" "titulo" => "Funding" ] 8 => array:2 [ "identificador" => "sec0045" "titulo" => "Conflict of Interest" ] 9 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "apendice" => array:1 [ 0 => array:1 [ "seccion" => array:1 [ 0 => array:4 [ "apendice" => "<p id="par0155" class="elsevierStylePara elsevierViewall">The following are the supplementary data to this article:<elsevierMultimedia ident="upi0005"></elsevierMultimedia></p>" "etiqueta" => "Appendix B" "titulo" => "Supplementary Data" "identificador" => "sec0060" ] ] ] ] "multimedia" => array:3 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Abbreviations</span>: SITT: single-inhaler triple therapy; FEV<span class="elsevierStyleInf">1</span>: forced expiratory volume in 1 second; μL: microliter; LAMA: long-acting muscarinic antagonists; LABA: long-acting β2-agonists; ICS: inhaled corticosteroids; HR: hazard ratio; CI: confidence interval.</p><p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">1. Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, et al. Single inhaler extrafine triple therapy <span class="elsevierStyleItalic">versus</span> long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomized controlled trial. Lancet. 2017;389(10082):1919–29.</p><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">2. Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind, multi-center parallel-group study. Am J Respir Crit Care Med. 2020.</p><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">3. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, et al. Extrafine inhaled triple therapy <span class="elsevierStyleItalic">versus</span> dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomized controlled trial. Lancet. 2018;391(10125):1076–84.</p><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">4. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple <span class="elsevierStyleItalic">versus</span> dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–80.</p><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">5. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.</p><p id="spar0040" class="elsevierStyleSimplePara elsevierViewall">6. Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7(9):745–56.</p><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">7. Axson EL, Lewis A, Potts J, Pang M, Dickinson S, Vioix H, et al. Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMJ Open. 2020;10(9):e036455.</p><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">8. Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Res. 2018;4(2).</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "fx1.jpeg" "imagenAlto" => 2309 "imagenAncho" => 3500 "imagenTamanyo" => 845784 ] ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Summary of the Main Results of the Meta-analysis at 52 Weeks. Green Color Represents Comparisons With Higher Level of Evidence in Favor of Single-inhaler Triple Therapy (Meta-analysis or Clear Effect From Randomized Clinical Trials). Yellow Color Depicts Contradictory Results or an Absence of Difference Between Treatment Groups Across Several Comparisons. Light Blue Color Indicates Lacking Data. For Each Result the Study References are Provided.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall"><span class="elsevierStyleItalic">Abbreviations</span>: COPD: chronic obstructive pulmonary disease; LAMA: long-acting muscarinic antagonists; LABA: long-acting β2-agonists; ICS: inhaled corticosteroids; SITT: single-inhaler triple therapy; BF: budesonide/formoterol; FEV<span class="elsevierStyleInf">1</span>: forced expiratory volume in 1 second; ml: milliliter; SGRQ: St. George's Respiratory Questionnaire; Dif.: difference; HR: hazard ratio; CI: confidence interval.</p><p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">1. Halpin DMG, Birk R, Brealey N, Criner GJ, Dransfield MT, Hilton E, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses. ERJ Open Res. 2018;4(2).</p><p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">2. Han MK, Criner GJ, Dransfield MT, Halpin DMG, Jones CE, Kilbride S, et al. The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind, multicenter clinical trial. Am J Respir Crit Care Med. 2020;202(9):1237–43.</p><p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">3. Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35–48.</p><p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">4. Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201(12):1508–16.</p><p id="spar0085" class="elsevierStyleSimplePara elsevierViewall">5. Martinez FJ, Rabe KF, Ferguson GT, Wedzicha JA, Singh D, Wang C, et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind, multi-center parallel-group study. Am J Respir Crit Care Med. 2020.</p>" "tablatextoimagen" => array:1 [ 0 => array:1 [ "tablaImagen" => array:1 [ 0 => array:4 [ "imagenFichero" => "fx2.jpeg" "imagenAlto" => 1187 "imagenAncho" => 3508 "imagenTamanyo" => 437510 ] ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Main Results of Single-inhaler Triple Therapy at 52 Weeks According to COPD Medication at Screening. Green Color Represents Comparisons With Statistically Significant Evidence in Favor of Single-inhaler Triple Therapy. Yellow Color Depicts Contradictory Results or an Absence of Difference Between Treatment Groups. Light Blue Color Indicates Lacking Data.</p>" ] ] 2 => array:5 [ "identificador" => "upi0005" "tipo" => "MULTIMEDIAECOMPONENTE" "mostrarFloat" => false "mostrarDisplay" => true "Ecomponente" => array:2 [ "fichero" => "mmc1.pdf" "ficheroTamanyo" => 430282 ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0100" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.M.G. Halpin" 1 => "R. Birk" 2 => "N. Brealey" 3 => "G.J. Criner" 4 => "M.T. Dransfield" 5 => "E. Hilton" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1183/23120541.00119-2017" "Revista" => array:4 [ "tituloSerie" => "ERJ Open Res" "fecha" => "2018" "volumen" => "4" "itemHostRev" => array:3 [ "pii" => "S0035378721006172" "estado" => "S300" "issn" => "00353787" ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0105" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Once-daily single-inhaler triple versus dual therapy in patients with COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.A. Lipson" 1 => "F. Barnhart" 2 => "N. Brealey" 3 => "J. Brooks" 4 => "G.J. Criner" 5 => "N.C. Day" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1713901" "Revista" => array:7 [ "tituloSerie" => "N Engl J Med" "fecha" => "2018" "volumen" => "378" "paginaInicial" => "1671" "paginaFinal" => "1680" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29668352" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0035378721006123" "estado" => "S300" "issn" => "00353787" ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0110" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "D.A. Lipson" 1 => "C. Crim" 2 => "G.J. Criner" 3 => "N.C. Day" 4 => "M.T. Dransfield" 5 => "D.M.G. Halpin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201911-2207OC" "Revista" => array:7 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2020" "volumen" => "201" "paginaInicial" => "1508" "paginaFinal" => "1516" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32162970" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0733861919300581" "estado" => "S300" "issn" => "07338619" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0115" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for COPD: a randomized, double-blind multi-center parallel-group study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F.J. Martinez" 1 => "K.F. Rabe" 2 => "G.T. Ferguson" 3 => "J.A. Wedzicha" 4 => "D. Singh" 5 => "C. Wang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.202006-2618OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2021" "volumen" => "203" "paginaInicial" => "553" "paginaFinal" => "564" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/33252985" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0120" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Papi" 1 => "J. Vestbo" 2 => "L. Fabbri" 3 => "M. Corradi" 4 => "H. Prunier" 5 => "G. Cohuet" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0140-6736(18)30206-x" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2018" "volumen" => "391" "numero" => "10125" "paginaInicial" => "1076" "paginaFinal" => "1084" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29429593" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0125" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S. Pascoe" 1 => "N. Barnes" 2 => "G. Brusselle" 3 => "C. Compton" 4 => "G.J. Criner" 5 => "M.T. Dransfield" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s2213-2600(19)30190-0" "Revista" => array:6 [ "tituloSerie" => "Lancet Respir Med" "fecha" => "2019" "volumen" => "7" "paginaInicial" => "745" "paginaFinal" => "756" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/31281061" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0130" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "K.F. Rabe" 1 => "F.J. Martinez" 2 => "G.T. Ferguson" 3 => "C. Wang" 4 => "D. Singh" 5 => "J.A. Wedzicha" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1056/NEJMoa1916046" "Revista" => array:6 [ "tituloSerie" => "N Engl J Med" "fecha" => "2020" "volumen" => "383" "paginaInicial" => "35" "paginaFinal" => "48" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32579807" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0135" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Vestbo" 1 => "A. Papi" 2 => "M. Corradi" 3 => "V. Blazhko" 4 => "I. Montagna" 5 => "C. Francisco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/s0140-6736(17)30188-5" "Revista" => array:7 [ "tituloSerie" => "Lancet" "fecha" => "2017" "volumen" => "389" "numero" => "10082" "paginaInicial" => "1919" "paginaFinal" => "1929" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28385353" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0140" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The effect of inhaled corticosteroid withdrawal and baseline inhaled treatment on exacerbations in the IMPACT study. A randomized, double-blind multicenter clinical trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M.K. Han" 1 => "G.J. Criner" 2 => "M.T. Dransfield" 3 => "D.M.G. Halpin" 4 => "C.E. Jones" 5 => "S. Kilbride" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1164/rccm.201912-2478OC" "Revista" => array:6 [ "tituloSerie" => "Am J Respir Crit Care Med" "fecha" => "2020" "volumen" => "202" "paginaInicial" => "1237" "paginaFinal" => "1243" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32584168" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0145" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Inhaled therapies for chronic obstructive pulmonary disease: a systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.L. Axson" 1 => "A. Lewis" 2 => "J. Potts" 3 => "M. Pang" 4 => "S. Dickinson" 5 => "H. Vioix" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1136/bmjopen-2019-036455" "Revista" => array:6 [ "tituloSerie" => "BMJ Open" "fecha" => "2020" "volumen" => "10" "paginaInicial" => "e036455" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/32994234" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0035378721004574" "estado" => "S300" "issn" => "00353787" ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/03002896/0000006000000001/v3_202406051404/S0300289623003587/v3_202406051404/en/main.assets" "Apartado" => array:4 [ "identificador" => "93560" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Scientific Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/03002896/0000006000000001/v3_202406051404/S0300289623003587/v3_202406051404/en/main.pdf?idApp=UINPBA00003Z&text.app=https://archbronconeumol.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0300289623003587?idApp=UINPBA00003Z" ]
